A landmark study demonstrates that CMR-derived extracellular volume (ECV) mapping effectively monitors amyloid burden in ATTR-CM. While untreated patients show significant progression, patisiran stabilizes amyloid load, with ECV progression serving as a potent independent predictor of mortality.